Edition:
United States

Aerie Pharmaceuticals Inc (AERI.OQ)

AERI.OQ on NASDAQ Stock Exchange Global Market

64.80USD
19 Jun 2018
Change (% chg)

$0.35 (+0.54%)
Prev Close
$64.45
Open
$63.95
Day's High
$65.75
Day's Low
$63.35
Volume
204,979
Avg. Vol
112,621
52-wk High
$66.55
52-wk Low
$47.05

Latest Key Developments (Source: Significant Developments)

Aerie Pharmaceuticals Reports Q1 Adjusted Loss Per Share $0.83
Tuesday, 8 May 2018 04:01pm EDT 

May 8 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 ADJUSTED LOSS PER SHARE $0.83.Q1 GAAP LOSS PER SHARE $1.05.Q1 EARNINGS PER SHARE VIEW $-0.87 -- THOMSON REUTERS I/B/E/S.  Full Article

Aerie Pharmaceuticals Reports Q4 Adjusted Loss Per Share $1.38
Wednesday, 28 Feb 2018 04:01pm EST 

Feb 28 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE AND 2018 GUIDANCE.Q4 ADJUSTED LOSS PER SHARE $1.38.Q4 GAAP LOSS PER SHARE $1.60.‍EXPECTS CASH BURN FOR FULL YEAR 2018 IN RANGE OF $200 MILLION TO $210 MILLION​.  Full Article

Aerie Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
Wednesday, 24 Jan 2018 06:30am EST 

Jan 24 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.AERIE PHARMACEUTICALS INC - ‍PRICED ITS REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $75 MILLION OF SHARES OF ITS COMMON STOCK​.  Full Article

Aerie Pharma Enters Controlled Equity Offering Sales Agreement With Cantor Fitzgerald
Tuesday, 19 Dec 2017 06:30am EST 

Dec 19 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMA SAYS ON DEC 19, CO ENTERED INTO CONTROLLED EQUITY OFFERING(SM)SALES AGREEMENT WITH CANTOR FITZGERALD - SEC FILING.AERIE PHARMACEUTICALS - PURSUANT TO AGREEMENT, CO MAY OFFER AND SELL SHARES, PAR VALUE $0.001 PER SHARE, HAVING OFFERING PRICE OF UP TO $75 MILLION.  Full Article

Aerie Pharmaceuticals Gets U.S. FDA Approval Of Glaucoma Drug
Monday, 18 Dec 2017 03:52pm EST 

Dec 18 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES U.S. FDA APPROVAL OF RHOPRESSA® (NETARSUDIL OPHTHALMIC SOLUTION) 0.02% FOR THE LOWERING OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION.AERIE PHARMACEUTICALS INC - REMAIN ON TRACK TO FILE ROCLATAN NEW DRUG APPLICATION TO FDA IN Q2 2018.AERIE PHARMACEUTICALS - RHOPRESSA APPROVED AHEAD OF SCHEDULED PDUFA DATE OF FEBRUARY 28, 2018.  Full Article

Aerie Pharma initiates netarsudil ophthalmic solution Phase 2 clinical trial
Thursday, 16 Nov 2017 04:01pm EST 

Nov 16 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals initiates netarsudil ophthalmic solution Phase 2 clinical trial designed to meet requirements of regulatory filing in Japan.Aerie Pharmaceuticals Inc - ‍for Rhopressa, U.S. FDA PDUFA goal date of February 28, 2018​.  Full Article

Aerie Pharmaceuticals Q3 loss per share $0.89
Wednesday, 8 Nov 2017 04:01pm EST 

Nov 8 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals reports third quarter 2017 financial results and provides business update.Q3 adjusted loss per share $0.71.Q3 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.Q3 gaap loss per share $0.89.Aerie Pharmaceuticals Inc - ‍as of september 30, 2017, Aerie had $282.2 million in cash, cash equivalents and investments​.  Full Article

Aerie Pharmaceuticals says ‍FDA committee to review NDA for Rhopressa
Friday, 13 Oct 2017 07:05am EDT 

Oct 13 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals Inc - ‍FDA advisory committee to review new drug application for Rhopressa (netarsudil ophthalmic solution) 0.02 pct​.  Full Article

Aerie Pharmaceuticals announces drug delivery asset acquisition
Thursday, 5 Oct 2017 06:00am EDT 

Oct 5 (Reuters) - Aerie Pharmaceuticals Inc : :Aerie Pharmaceuticals announces drug delivery asset acquisition to further advance its retinal disease program.Aerie Pharmaceuticals Inc - has acquired from Envisia Therapeutics Inc rights to use print technology in ophthalmology and certain other assets.Aerie Pharmaceuticals Inc - ‍Envisia will receive an initial $25 million in form of a combination of cash and Aerie common stock​.Aerie Pharmaceuticals Inc - expect to initiate ‍clinical trials for AR-13154 within next 18 to 24 months​.Aerie Pharmaceuticals Inc - ‍in addition, Aerie acquired Envisia's intellectual property rights relating to ENV1105​.  Full Article

Aerie Pharmaceuticals comments on notification from contract manufacturer
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals Inc - ‍received notification by its contract drug product manufacturer that contract manufacturer received CRL from U.S FDA.Aerie Pharmaceuticals - ‍CRL from FDA regarding contract manufacturer's NDA for one of their own product candidates manufactured at Tampa, Florida facility​.Aerie Pharmaceuticals Inc - ‍according to contract manufacturer, CRL refers to a Current Good Manufacturing Practice (CGMP) inspection at facility​.Aerie Pharmaceuticals Inc - ‍contract manufacturer has stated that they will work closely with FDA to determine appropriate next steps​.Aerie Pharmaceuticals Inc - ‍currently believe it is probable that open issues will be resolved prior to February 28, 2018 PDUFA date for Rhopressa​.  Full Article

BRIEF-Aerie Pharmaceuticals Submits NDA To U.S. FDA For Roclatantm

* AERIE PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR ROCLATANTM (NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005%